Essa Pharma Common shares had a trading volume of 22K on Tuesday. Volume was down 84.16% under the stocks average daily volume.
Traders are a little more bullish on shares of Essa Pharma Common lately if you evaluate the decrease in short interest. The stock had a fall in short interest of -44.64% as of the latest report on October 13, 2017. Short shares decreased from 56,836 to 31,462 over that period. The short-interest ratio decreased to 0.0 and the percentage of shorted shares was inf% on October 13.
These firms have modified their investment in EPIX. Tower Research Capital LLC (trc) trimmed its investment by selling 1,799 shares a decrease of 81.8% as of 03/31/2017. Tower Research Capital LLC (trc) claims 400 shares valued at $1,000. The total value of its holdings decreased 80.0%. Toronto Dominion Bank expanded its ownership by buying 338 shares an increase of 545.2% from 03/31/2017 to 06/30/2017. Toronto Dominion Bank now controls 400 shares worth $0. The value of the position overall is down by nan%.
August 3 investment analysts at Dawson James maintained a “Buy” rating on the company.
The company is now unchanged since yesterday’s close of .
ESSA Pharma Inc., a clinical-stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that blocks the N-terminal domain of the androgen receptor. The company was founded in 2009 and is headquartered in Vancouver, Canada..